A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Endocrine System Diseases Clinical Trial

— PaTH Forward  

Official title:

PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04009291
• Other study ID #: TransCon PTH TCP-201
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 27, 2019
• Est. completion date: March 2025

Study information

• Verified date: June 2024
• Source: Ascendis Pharma A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

During the first four weeks of the trial, participants will be randomly assigned to one of four groups: three groups will receive fixed doses of TransCon PTH and one group will receive placebo. TransCon PTH or placebo will be administered as a subcutaneous injection using a pre-filled injection pen. Neither trial participants nor their doctors will know who has been assigned to each group. After the four weeks, participants will continue in the trial as part of a long-term extension study. During the extension, all participants will receive TransCon PTH, with the dose adjusted to their individual needs. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Germany, Denmark, and Norway.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 59
• Est. completion date: March 2025
• Est. primary completion date: March 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males and females aged =18 years.

2. Subjects with postsurgical chronic HP or auto-immune, genetic, or idiopathic HP for at least 26 weeks.

3. On a stable dose for at least 12 weeks (or 4 weeks if on Natpara as of September 2019) prior to Screening of:

• =0.25 µg BID of calcitriol (active vitamin D) or =0.5 µg BID or =1.0 µg daily of alfacalcidol (active vitamin D), and

• =400 mg BID calcium citrate or carbonate.

4. Optimization of supplements prior to randomization to achieve the target levels of:

• 25(OH) vitamin D levels of 30-70 ng/mL (75-175 pmol/mL) and

• Magnesium level within the normal range and

• Albumin-adjusted or ionized serum calcium (sCa) level in the lower half of the normal range.

5. BMI 17-40 kg/m2 at Visit 1.

6. If =25 years of age, radiological evidence of epiphyseal closure based on x-ray of non-dominant wrist and hand.

7. eGFR >30 mL/min/1.73m2 during Screening.

8. Thyroid-stimulating hormone (TSH) within normal laboratory limits within the 12 weeks prior to Visit 1; if on suppressive therapy for thyroid cancer, TSH level must be =0.2 µIU/mL.

9. If treated with thyroid hormone replacement therapy, the dose must be stable for at least 12 weeks prior to Visit 1.

10. Able to perform daily subcutaneous self-injections of study drug (or have a designee perform injection) via a pre-filled injection pen.

11. Written, signed, informed consent of the subject.

Exclusion Criteria:

1. Known activating mutation in the calcium-sensing receptor (CaSR) gene.

2. Impaired responsiveness to PTH (pseudohypoparathyroidism) which is characterized as PTH-resistance, with elevated PTH Levels in the setting of hypocalcemia.

3. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP, such as active hyperthyroidism; Paget's disease; hypomagnesemia; type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus; severe and chronic cardiac, liver, or renal disease; Cushing syndrome; rheumatoid arthritis; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobility; active malignancy (other than low-risk well differentiated thyroid cancer or basal cell skin cancer); parathyroid carcinoma within 5 years prior to Screening; acromegaly; multiple endocrine neoplasia types 1 and 2.

4. Use of loop diuretics, phosphate binders (other than calcium carbonate/calcium citrate), digoxin, lithium, methotrexate, or systemic corticosteroids (other than replacement therapy).

5. Use of thiazide diuretic within 4 weeks prior to the Screening 24-hour urine collection or the first dose adjustment of SOC during Screening.

6. Use of PTH-like drugs (whether commercially available or through participation in an investigational trial) including PTH(1-84), PTH(1-34), or other N-terminal fragments or analogs of PTH or PTH-related protein within 5 weeks prior to Visit 1.

7. Use of other drugs known to influence calcium and bone metabolism, such as calcitonin, fluoride tablets (> 0.5 mg/day), strontium, or cinacalcet hydrochloride within 12 weeks prior to Visit 1.

8. Use of bisphosphonates (oral or IV) or denosumab within 2 years prior to Visit 1.

9. Non-hypocalcemic seizure disorder with a history of a seizure within 26 weeks prior to Visit 1.

10. Increased risk for osteosarcoma, such as those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, hereditary disorders predisposing to osteosarcoma, or with a prior history of substantial external beam or implant radiation therapy involving the skeleton.

11. Pregnant or lactating women. Note: Highly effective contraception (see Appendix 7) is required for sexually active women of childbearing potential during the trial and for 2 weeks after the last dose of study drug, and pregnancy testing will be performed throughout the trial. Sexually active women of childbearing potential who are unwilling to use highly effective contraception are excluded from the trial.

12. Diagnosis of drug or alcohol dependence within 3 years prior to Visit 1.

13. Disease processes that may adversely affect gastrointestinal absorption including but not limited to short bowel syndrome, bowel resection, gastric bypass, tropical sprue, active celiac disease, active ulcerative colitis, gastroparesis, AIRE gene mutations with malabsorption, and active Crohn's disease.

14. Chronic or severe cardiac disease within 26 weeks prior to Visit 1 including but not limited to congestive heart failure, myocardial infarction, QTcF >430 msec (males) or >450 msec (females), severe or uncontrolled arrhythmias, bradycardia (resting heart rate <50 beats/minute), symptomatic hypotension, systolic BP <80 mm Hg or diastolic <40 mm Hg, or poorly controlled hypertension (systolic BP >150 mm Hg or diastolic >95 mm Hg).

15. Cerebrovascular accident within 5 years prior to Visit 1.

16. History of renal colic or acute gout within 52 weeks prior to Visit 1.

17. Any disease or condition that, in the opinion of the investigator, may make the subject unlikely to fully complete the trial, or any condition that presents undue risk from the investigational product or procedures, including treated malignancies that are likely to recur within the approximate 1-year duration of the trial.

18. Known allergy or sensitivity to PTH or any of the excipients.

19. Participation in another clinical trial in which receipt of investigational drug or device occurred within 8 weeks (or at least 5.5 times the half-life of the investigational drug) prior to Visit 1.

20. Likely to be non-compliant with respect to trial conduct.

Related Conditions & MeSH terms

• Endocrine System Diseases
• Hypoparathyroidism
• Parathyroid Diseases

Intervention

Combination Product:
• TransCon PTH
TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
• Placebo for TransCon PTH
Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.

Locations

Country	Name	City	State
Canada	Ascendis Pharma Investigational Site	Oakville	Ontario
Denmark	Ascendis Pharma Investigational Site	Aalborg
Denmark	Ascendis Pharma Investigational Site	Aarhus
Denmark	Ascendis Pharma Investigational Site	Kobenhavn
Germany	Ascendis Pharma Investigational Site	Dresden
Italy	Ascendis Pharma Investigational Site	Bologna
Italy	Ascendis Pharma Investigational Site	Milan
Italy	Ascendis Pharma Investigational Site	Pisa
Italy	Ascendis Pharma Investigational Site	Rome
Norway	Ascendis Pharma Investigational Site	Oslo
United States	Ascendis Pharma Investigational Site	Chicago	Illinois
United States	Ascendis Pharma Investigational Site	Great Neck	New York
United States	Ascendis Pharma Investigational Site	New York	New York
United States	Ascendis Pharma Investigational Site	Philadelphia	Pennsylvania
United States	Ascendis Pharma Investigational Site	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Ascendis Pharma A/S

Countries where clinical trial is conducted

United States,  Canada,  Denmark,  Germany,  Italy,  Norway, 

References & Publications (1)

Khan AA, Rejnmark L, Rubin M, Schwarz P, Vokes T, Clarke B, Ahmed I, Hofbauer L, Marcocci C, Pagotto U, Palermo A, Eriksen E, Brod M, Markova D, Smith A, Pihl S, Mourya S, Karpf DB, Shu AD. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phas — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy - Primary Endpoint During the Blinded Period	The percentage of subjects with albumin-adjusted serum calcium within the normal range, and spot morning fractional excretion of calcium (spot AM FECa) within normal range (=2%) or a reduction by at least 50% from baseline, and not taking active vitamin D supplements, and taking =1000 mg/day of calcium supplements	Week 4
Secondary	Efficacy - Key Secondary Endpoint During the Blinded Period	The percentage of subjects with albumin-adjusted serum calcium within the normal range, and spot AM FECa within the normal range (=2%) or a reduction by at least 50% from baseline, and not taking active vitamin D supplements, and taking = 500 mg/day of calcium supplements	Week 4